A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

Inclusion Criteria: * 18 to 65 years of age, inclusive * Body weight at least 50 kg * Healthy male or female subjects (Healthy Cohorts) * Body mass index (BMI) 18 to 30 kg/m\^2, inclusive (Healthy Cohorts) * Nonsmoker for at least 90 days prior to dosing (Healthy Cohorts) * Primary diagnosis of MDD without psychotic features (MDD Cohort) * BMI 18 to 35 kg/m\^2, inclusive (MDD Cohort) * Current partial response to ongoing SSRI or SNRI antidepressant treatment at an adequate dose and for at least 4 weeks (MDD Cohort) * Clinical Global Impression of Severity (CGI-S) score 3 or greater (MDD Cohort) * Other regimens stable for at least 8 weeks prior to screening (MDD Cohort) Exclusion Criteria: * Pregnant or lactating women * History of alcohol or substance abuse in the past 6 months * Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) * Clinically relevant electrocardiogram (ECG) abnormalities or a personal or family history of congenital long QT syndrome * Participation in an investigational study within 90 days of screening * Blood donation over 500 mL within 3 months of screening * Hypersensitivity to any study medication or excipients * Psychotic symptoms or comorbid mood disorder * Significant suicide risk * Major illness within 1 month before screening, or febrile illness within 1 week (Healthy Cohorts) * Average alcohol consumption of more than 2 units per day (Healthy Cohorts) * Multi-drug therapy for depression including antidepressants or adjunctive medications (MDD Cohort) * Prior use of basimglurant (MDD Cohort) * Cigarette use of greater than 1 pack per day (MDD Cohort)